NDAORALTABLET, DELAYED RELEASE
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
THIOLA EC (tiopronin) by Mission Pharmacal is cystine disulfide reduction [moa]. Approved for reducing and complexing thiol [epc]. First approved in 2019.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THIOLA EC (tiopronin) is an oral delayed-release tablet that reduces cystine disulfide through a chelating mechanism, indicated for cystinuria. It works by converting urinary cystine into soluble disulfide compounds, preventing kidney stone formation in patients with this rare genetic disorder.
$23MPart D
Peak12.4 years to LOEStable niche market in peak lifecycle with small claim volume; limited team expansion expected as product matures in rare disease segment.
Mechanism of Action
Cystine Disulfide Reduction
Pharmacologic Class:
Reducing and Complexing Thiol
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunities for THIOLA EC are concentrated in manufacturing and facilities operations rather than commercial or medical roles, reflecting Mission Pharmacal's production-focused operations. This suggests a smaller commercial team with emphasis on supply chain stability for a niche rare disease product.
ELECTRICIAN
Worked on THIOLA EC at Mission Pharmacal? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.